Clinical trials: Ulcerative Colitis, Active
Colitis, Ulcerative
Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients
Ulcerative colitis (UC) represents one of the major entities of idiopathic inflammatory bowel diseases which are defined as chronically relapsing inflammations of the gastrointestinal tract not due to specific pathogens.
- Trial name
- SECURE (NCT02129439)
- Testing
- SB012
- Where
- 3 sites in Germany
- Volunteers
- 20 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Colitis, Ulcerative
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
This is a Phase 2, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the safety, tolerability, efficacy and dose-response of GSK2831781 in participants with moderate to severe active…
- Trial name
- NCT03893565
- Testing
- GSK2831781 - Double Blind Phase, GSK2831781 - Open Label phase
- Where
- 61 sites in United States, Bulgaria and 13 more
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis, Inflammatory Bowel Diseases
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)
The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderately to severely active UC.
- Conditions
- Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
- Trial name
- Aegean (NCT07513181)
- Testing
- ATH-063
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Athos Therapeutics Inc
Ulcerative Colitis
A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of AC-101 tablets in participants with moderate-to-severe ulcerative colitis.
- Trial name
- NCT07083193
- Testing
- AC-101
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Colitis, Ulcerative
Phase III Multicentre Trial of Oral Mesalazine in Patients With Mild to Moderate Ulcerative Colitis.
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
- Trial name
- NCT06176560
- Testing
- Mesalazine
- Volunteers
- 376 people
- Sponsor
- Faes Farma, S.A.
Ulcerative Colitis
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- ELEVATE UC 12 (NCT03996369)
- Testing
- Etrasimod
- Where
- 407 sites in United States, Argentina and 39 more
- Volunteers
- 354 people
- Sponsor
- Arena Pharmaceuticals
Ulcerative Colitis
Open-label Extension Study of Brazikumab in Ulcerative Colitis
The purpose of this OLE Study D5272C00002 (Legacy #3151-202-008) is to permit participants who previously enrolled in the double-blind Study D5272C00001 (Legacy #3151-201-008) to receive brazikumab, allowing for long-term…
- Trial name
- Expedition (NCT04277546)
- Testing
- Brazikumab Maintenance Dose, Brazikumab Induction Dose
- Where
- 36 sites in United States, Czechia and 9 more
- Volunteers
- 57 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and…
- Trial name
- SELECTION (NCT02914522)
- Testing
- Filgotinib, PTM filgotinib
- Where
- 343 sites in United States, Argentina and 38 more
- Volunteers
- 1,351 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of…
- Trial name
- NCT06137183
- Testing
- Vixarelimab
- Where
- 65 sites in United States, Brazil and 10 more
- Volunteers
- 79 people
- Sponsor
- Genentech, Inc.
Ulcerative Colitis
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will evaluate how safe and effective risankizumab is…
- Trial name
- REVAMP (NCT06880744)
- Testing
- Risankizumab, Vedolizumab
- Where
- 270 sites in United States, Austria and 29 more
- Volunteers
- 573 people
- Sponsor
- AbbVie
Ulcerative Colitis
Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis
This study is to evaluate the efficacy and tolerability of multiple oral doses of Natura-alpha capsule administered to patients with active ulcerative colitis.
- Trial name
- NCT01216280
- Testing
- 2 x 10 mg Natura-alpha capsules
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Natrogen Therapeutics International, Inc
Ulcerative Colitis
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-101 clinical study…
- Trial name
- NCT03368118
- Testing
- ABX464
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- Abivax S.A.
Inflammation, Ulcerative Colitis
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis
This trial is conducted in Europe. The aim of the trial is to investigate the effect of recombinant factor XIII (rFXIII) administered to subjects with mild to moderate active ulcerative colitis (UC).
- Trial name
- NCT01706159
- Testing
- catridecacog
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Colitis, Ulcerative
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC)
The purpose of this study is to prove the therapeutic equivalence and safety of once-daily 9 mg budesonide versus 3 g mesalazine in a 8-week treatment in patients with active ulcerative colitis.
- Trial name
- NCT00747110
- Testing
- budesonide, mesalazine
- Where
- Germany
- Volunteers
- 343 people
- Sponsor
- Dr. Falk Pharma GmbH
Ulcerative Colitis
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.
- Trial name
- NCT04898348
- Testing
- KBL697
- Where
- Australia
- Sponsor
- KoBioLabs
Colitis, Ulcerative
Confirmatory Clinical Study in Active Ulcerative Colitis
The main goal of the study is to check if MH002 works and is safe to use. In a previous study in 45 patients with Ulcerative Colitis, MH002 was found to have favorable effects.
- Trial name
- StarFish-UC (NCT07296315)
- Testing
- Low-dose MH002, High-dose MH002
- Where
- 49 sites in United States, Czechia and 5 more
- Volunteers
- 204 people
- Sponsor
- MRM Health NV
Ulcerative Colitis
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (QD) at 25 mg in subjects who have been previously enrolled in the ABX464-102 or ABX464-104 studies…
- Trial name
- NCT05177835
- Testing
- ABX464
- Where
- 46 sites in Austria, Belgium and 12 more
- Volunteers
- 203 people
- Sponsor
- Abivax S.A.
Ulcerative Colitis
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
The goal of this study is to learn if emvistegrast (formerly GS-1427) is effective in treating participants with moderate to severe ulcerative colitis.
- Trial name
- SWIFT (NCT06290934)
- Testing
- emvistegrast
- Where
- 181 sites in United States, Australia and 20 more
- Volunteers
- 228 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
The purpose of this study is to evaluate efficacy and safety of ZYIL1 oral capsule twice a day for 12 weeks for treatment of mild to moderate active ulcerative colitis resistant or intolerant to oral aminosalicylates.
- Trial name
- NCT06398808
- Testing
- Arm1, Arm 2
- Where
- India
- Volunteers
- 24 people
- Sponsor
- Zydus Lifesciences Limited
Ulcerative Colitis (UC)
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the…
- Trial name
- NCT03398148
- Testing
- risankizumab IV, risankizumab SC
- Where
- 430 sites in United States, Argentina and 42 more
- Volunteers
- 1,558 people
- Sponsor
- AbbVie